Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

New medicinal application of MK-5046

A kind of MK-5046, a pharmaceutical technology, applied in the field of medicine, can solve the problem of no endogenous cardiomyocyte proliferation, and achieve the effect of promoting cardiomyocyte proliferation

Pending Publication Date: 2022-06-21
SYNOGENBIOPHARMACO LTD NANJING CHINA +1
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is no report on the induction of endogenous cardiomyocyte proliferation by MK-5046

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • New medicinal application of MK-5046
  • New medicinal application of MK-5046

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] Embodiment 1, the in vitro test of MK-5046 promoting the proliferation of rat cardiomyocytes

[0032] (1) Culture of Cardiomyocytes of SD Rats

[0033] Cardiomyocytes from SD rats born 3 days old were isolated and cultured in DMEM high glucose medium (Hyclone) + 5% horse serum (GIBCO) at 37 degrees in a 5% carbon dioxide incubator.

[0034] (2) Experimental grouping and processing

[0035] Isolate cardiomyocytes from SD rats, add 5% horse serum (GIBCO) + DMEM high-glucose medium (Hyclone), and add cytarabine (final concentration 20umol / L) to inhibit the growth of non-cardiomyocytes. Infect cTnT-mAG-hGeminin (1 / 110) virus (MOI value of virus infection=100) after 48 hours of adherence, after another 24 hours, replace with DMEM culture medium containing 0.5% FBS, add drugs in groups, and group as follows:

[0036] a. Experimental group: treated with MK-5046 (the final concentration in the medium is 2 μmol / L) for 24 hours.

[0037] b. Blank control group: add the same am...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a medicinal application of MK-5046 (MK-5046). The application refers to application of MK-5046 or pharmaceutically acceptable salt thereof in preparation of drugs for promoting myocardial cell proliferation. Experiments prove that MK-5046 can promote proliferation of myocardial cells of rats. Therefore, the MK-5046 can be used in the related fields of preparation of drugs for promoting myocardial cell proliferation, drugs for treating or preventing heart diseases and the like, and a new drug and a treatment thought are provided for treating or preventing heart diseases such as myocardial infarction.

Description

technical field [0001] The invention belongs to the field of medicine, and in particular relates to a new medicine application of MK-5046. Background technique [0002] At present, cardiovascular disease has become the number one killer threatening human health. There are 40 million heart failure patients worldwide, and it has become the main cause of human death. Studies have found that cardiomyocytes in mammals gradually lose their ability to proliferate after adulthood. Once myocardial infarction occurs, the loss of cardiomyocytes will be irreversible. There are about 2-4 billion cardiomyocytes in an adult, about 25% of cardiomyocytes will be lost within a few hours after myocardial infarction, and the remaining cardiomyocytes have very limited proliferation ability, which is not enough to restore the contractile function of the heart, and the patient will eventually suffer from heart failure die. To solve this problem, in addition to surgery, basic translational resear...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/4178A61P9/00A61P9/10A61P9/04C12N5/077
CPCA61K31/4178A61P9/00A61P9/10A61P9/04C12N5/0657C12N2501/999
Inventor 卜晔杜建勇郑丽霞吴青朱小君熊敬维
Owner SYNOGENBIOPHARMACO LTD NANJING CHINA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products